Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
NXC-201 / Immix Biopharma
NEXICART-1, NCT04720313: NXC-201 (formerly HBI0101) Multiple Myeloma	Active, not recruiting	1	160	RoW	NXC-201 (formerly HBI0101)	Hadassah Medical Organization, Nexcella Inc.	Dose Escalation and Safety	01/26	01/27
NEXICART-2, NCT06097832: Study of NXC-201 CAR-T in Patients with Light Chain (AL) Amyloidosis	Recruiting	1	40	US	NXC-201 CAR-T, HBI0101 CAR-T	Nexcella Inc., Immix Biopharma, Inc.	Light Chain (AL) Amyloidosis	12/26	01/39

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
NXC-201 / Immix Biopharma
NEXICART-1, NCT04720313: NXC-201 (formerly HBI0101) Multiple Myeloma	Active, not recruiting	1	160	RoW	NXC-201 (formerly HBI0101)	Hadassah Medical Organization, Nexcella Inc.	Dose Escalation and Safety	01/26	01/27
NEXICART-2, NCT06097832: Study of NXC-201 CAR-T in Patients with Light Chain (AL) Amyloidosis	Recruiting	1	40	US	NXC-201 CAR-T, HBI0101 CAR-T	Nexcella Inc., Immix Biopharma, Inc.	Light Chain (AL) Amyloidosis	12/26	01/39